Female androgenetic alopecia is a challenging condition to treat. Available therapies provide limited benefits, and the condition is associated with a significant potential effect on the patient's self-confidence and quality of life. PharmaGenoma and its subsidiary HairDX will soon commence a clinical trial of a genetically tailored therapy for female AA (hairdx.com). The company has already begun recruiting post-menopausal women as subjects for enrollment. Women who qualify will undergo genetic screening; Those who exhibit a particular genetic variation in their Androgen Receptor gene, will receive a tailored therapy that may potentially re-grow their hair.

"Our goal is to revolutionize the field of dermatology by innovating genetically tailored treatments to common skin disorders," said Andy Goren, Chairman and Chief Strategist of PharmaGenoma and HairDX, in a statement.

Since there are very few treatment options for female baldness currently approved, news of this trial offers patients hope that the future is bright. "Dermatologists often prescribe women drugs for the treatment of hair loss; however, only a fraction of women respond to the therapy. If the HairDX clinical trial proves successful, dermatology will be able to individually tailor treatment for hair loss based on a woman's genetic makeup," said Professor Doron Lancet, Head of the Crown Human Genome Center at the Department of Molecular Genetics, Weizmann Institute of Science.